OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.8 EUR 1.4% Market Closed
Market Cap: 127.3m EUR

OSE Immunotherapeutics SA
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

OSE Immunotherapeutics SA
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Other Equity
-€1k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Other Equity
-€3.2m
CAGR 3-Years
-1 366%
CAGR 5-Years
-401%
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Other Equity
-€454k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Other Equity
-€1k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Other Equity
-$12.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Other Equity
-€1k
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A

OSE Immunotherapeutics SA
Glance View

Market Cap
126.6m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
3.74 EUR
Overvaluation 36%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Other Equity?
Other Equity
-1k EUR

Based on the financial report for Dec 31, 2024, OSE Immunotherapeutics SA's Other Equity amounts to -1k EUR.

Back to Top